Understanding the Latest Therapeutic Advances in Multiple Myeloma

Join us for a live CME/CE-certified event to hear from experts on the latest data and therapeutic options for patients with myeloma.

Agenda

Introduction and Overview of Myeloma

Case Discussion 1: When Should Systemic Myeloma Treatment Be Initiated?

  • Accurate diagnosis of MM and assessment of risk
  • Techniques and biomarkers for diagnosis

Case Discussion 2: Individualized Approaches to Frontline Treatment

  • Understanding how patient and disease factors guide therapy decisions
  • Optimal induction, consolidation, and maintenance approaches for individual patients
  • Supportive care strategies for patients undergoing treatment for MM

Case Discussion 3: Therapeutic Strategies for Relapsed or Refractory Myeloma

  • Planning optimal agent combinations for therapy
  • New and future options for relapsed/refractory disease

Conclusions and Audience Question and Answer Session

Events

Date / Time
Event Details
2/5/2019
7:30 AM

Understanding the Latest Therapeutic Advances in Multiple Myeloma

Lansing, MI
Michigan State University Hematology/Oncology Fellowship Program Details
3/12/2019
12:00 PM
3/13/2019
8:00 AM
3/19/2019
6:00 PM

Faculty

Co-Chair
Shaji Kumar, MD

Department of Hematology
Mayo Clinic
Rochester, Minnesota

Co-Chair
Sagar Lonial, MD

Professor and Chair 
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

CME

Goal Statement
The goal of this activity is to improve participants’ competence to provide optimal care for patients with multiple myeloma.

Target Audience 
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with multiple myeloma.

Learning Objectives 

  • Integrate timely systemic treatment for appropriate patients based on current multiple myeloma diagnosis and staging criteria
  • Plan individualized treatment strategies for patients with multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
  • Identify ongoing trials of investigational approaches in the treatment of multiple myeloma to aid referral of patients for study participation

Accreditation

Physician Continuing Medical Education

Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
1.0 contact hour may be earned for successful completion of this activity.

Provider approved by the California Board of Registered Nursing, Provider Number 13664, for 1.0 contact hour. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Pharmacist Continuing Education

Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
This program has been assigned ACPE Universal Activity #0797-9999-18-222-L01-P. This program is designated for up to 1.0 contact hour (0.10 CEUs) of continuing pharmacy education credit. 

Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Type of Activity: Application

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.